Registration Dossier
Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 214-711-0 | CAS number: 1189-08-8
Endpoint summary
Administrative data
Description of key information
Oral administration:
A combination study of OECD 422/ 408 is ongoing with 1,3 -BDDMA. The results will be reported as soon as they will become available.
The current DNEL is based on available results with 1,3-butanediol (Reuzel, 1978) and will be updated as soon as the new data will become available.
Inhalation:
Based on physico-chemical data, the inhalation of the substance is very unlikely. Furthermore, spray-application are excluded.
Dermal administration:
Based on physico-chemical data, the dermal absorption of the substance is very low.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- repeated dose toxicity: oral, other
- Remarks:
- OECD 422 and OECD 408
- Data waiving:
- other justification
- Justification for data waiving:
- other:
- Justification for type of information:
- The performance of the OECD 422/408 is in delay and is currently being conducted. The results will be available presumably in Q3/2023. The results will be included in the assessment in the next dossier update.
- Principles of method if other than guideline:
- Combination study of OECD 422 and 408
- GLP compliance:
- yes
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Route of administration:
- oral: gavage
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 6 000 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Justification for classification or non-classification
Based on the available data, 1,3-BDDMA does not need to be classified for repeated dose toxicity according to the criteria given in regulation (EC) 1272/2008. Thus, no labelling is required.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
